ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter - PubMed (original) (raw)
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter
Robyn M B Loureiro et al. Biochem Biophys Res Commun. 2005.
Abstract
The angiogenic molecule, vascular endothelial growth factor (VEGF), is a critical regulator of normal and pathologic angiogenesis. ErbB2, an epidermal growth factor receptor family member whose overexpression in mammary tumors is correlated with poor patient prognosis, has been implicated as a positive modulator of VEGF expression. Mammary tumor cells overexpressing ErbB2 (NAFA cells) and a normal mouse mammary cell line (HC11) transfected with ErbB2 expression vectors were used to study the effects of ErbB2 overexpression on VEGF regulation. We found that ErbB2 overexpression led to an increase in endogenous VEGF mRNA as well as ErbB3 protein levels in HC11 cells. Additionally, we determined that ErbB2 overexpression-mediated upregulation of VEGF involves at least two distinct promoter elements, one previously identified as the hypoxia responsive element and the other the core promoter region (-161 to -51bp), which is specifically controlled via two adjacent SP1 binding sites (-80 to -60bp).
Similar articles
- ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. Klos KS, et al. Cancer Res. 2006 Feb 15;66(4):2028-37. doi: 10.1158/0008-5472.CAN-04-4559. Cancer Res. 2006. PMID: 16489002 - Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH. Pedersen NM, et al. Mol Cancer Res. 2009 Feb;7(2):275-84. doi: 10.1158/1541-7786.MCR-07-2183. Epub 2009 Feb 10. Mol Cancer Res. 2009. PMID: 19208749 - ErbB2 activation and signal transduction in normal and malignant mammary cells.
Hynes NE. Hynes NE. J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):199-206. doi: 10.1007/BF02013643. J Mammary Gland Biol Neoplasia. 1996. PMID: 10887493 Review.
Cited by
- Targeting Angiogenic Factors for the Treatment of Medulloblastoma.
Saker Z, Rizk M, Bahmad HF, Nabha SM. Saker Z, et al. Curr Treat Options Oncol. 2022 Jun;23(6):864-886. doi: 10.1007/s11864-022-00981-1. Epub 2022 Apr 12. Curr Treat Options Oncol. 2022. PMID: 35412196 Review. - Phosphorylation of STAT3 and ERBB2 mediates hypoxia‑induced VEGF release in ARPE‑19 cells.
Hwang S, Seong H, Ryu J, Jeong JY, Kang TS, Nam KY, Seo SW, Kim SJ, Kang SS, Han YS. Hwang S, et al. Mol Med Rep. 2020 Oct;22(4):2733-2740. doi: 10.3892/mmr.2020.11344. Epub 2020 Jul 16. Mol Med Rep. 2020. PMID: 32945388 Free PMC article. - Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Larionov AA. Larionov AA. Front Oncol. 2018 Apr 3;8:89. doi: 10.3389/fonc.2018.00089. eCollection 2018. Front Oncol. 2018. PMID: 29670855 Free PMC article. Review. - Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.
Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA. Jia D, et al. Blood. 2013 Jan 24;121(4):707-15. doi: 10.1182/blood-2012-05-433045. Epub 2012 Dec 3. Blood. 2013. PMID: 23212515 Free PMC article. - Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α.
Riddell JR, Maier P, Sass SN, Moser MT, Foster BA, Gollnick SO. Riddell JR, et al. PLoS One. 2012;7(11):e50394. doi: 10.1371/journal.pone.0050394. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185615 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous